Protein kinase C beta II (PKCβII) (PKCβII)

Protein kinase C beta II (PKCβII) is a calcium-dependent serine/threonine kinase and a member of the conventional PKC family, derived from the alternative splicing of the PRKCB gene (UniProt P05771). It is a central mediator in signal transduction pathways activated by diacylglycerol (DAG) and calcium, influencing processes such as cell proliferation, apoptosis, and vascular homeostasis (NCBI Gene ID: 5579). In pathological states, particularly diabetes, chronic hyperglycemia leads to the overactivation of PKCβII, which contributes to microvascular damage, including diabetic retinopathy and nephropathy, by promoting oxidative stress and VEGF expression (PubMed: 16175166). Furthermore, PKCβII is highly expressed in certain B-cell malignancies, where it supports tumor cell survival and proliferation through the B-cell receptor signaling pathway (PubMed: 15150102). Pharmacological targeting of PKCβII has primarily involved small-molecule inhibitors like ruboxistaurin and enzastaurin, which have been investigated for their potential to treat diabetic complications and various cancers, respectively (PubChem CID: 9836724). The enzyme's role in platelet activation also makes it a subject of interest in cardiovascular research regarding thrombosis (PubMed: 17403714). Despite its therapeutic potential, achieving high selectivity over other PKC isoforms remains a significant challenge in drug development (PubMed: 11511041).

Other names

PRKCBProtein kinase C beta typePKC-beta 2PKC-BIIPRKCB2PKC-beta-II

Selective or non-selective inhibition of the serine/threonine kinase activity by competing with ATP binding or modulating the regulatory domain.